Trial Profile
Randomized, controlled trial of the clinical effect of selecrive SGLT2 blocker, ipragliflozin, and DPP-4 blocker in type 2 diabetic patients with NAFLD/NASH.- multicenter study
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 15 Jan 2020
Price :
$35
*
At a glance
- Drugs Alpha-glucosidase inhibitors (Primary) ; Ipragliflozin (Primary) ; Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 12 Jan 2020 Status changed from active, no longer recruiting to completed.
- 22 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 23 May 2017 Status changed from not yet recruiting to recruiting.